Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new combo could shrink head and neck tumors before surgery

NCT ID NCT07524452

Recruiting now Disease control Sponsor: Ming-Yuan Chen Source: ClinicalTrials.gov ↗

First seen Apr 15, 2026 · Last updated May 19, 2026 · Updated 6 times

Summary

This study tests whether adding a targeted drug (becotatug vedotin) to standard immunotherapy works better than immunotherapy alone for people with a certain type of advanced head and neck cancer that can be removed by surgery. About 430 adults with EGFR-positive, CPS≥1 tumors will receive either the combination or immunotherapy alone before and after surgery. The goal is to see if the combination helps keep cancer from coming back longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Fifth Affiliated Hospital,Sun Yat-sen University

    RECRUITING

    Zhuhai, Guangdong, 519099, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA